Fujirebio, a member of H.U. Group Holdings Inc., is a global leader in the field of high-quality RUO and in vitro diagnostics (IVD) testing. It has more than 50 years’ accumulated experience in the ...

Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse® G sTREM2 Assay for Research Use Only H.U. Group Holdings Inc. and its wholly-owned subsidiary ...

Ixico said it was contracted by Fujirebio Diagnostics Inc, a Tokyo-based biomarker research company, to assist with the development of a new blood-based test for Alzheimer's disease called Lumipulse.

Fujirebio, a member of H.U. Group Holdings Inc., is a global leader in the field of high-quality RUO and in vitro diagnostics (IVD) testing. It has more than 50 years' accumulated experience in the ...

GENT, Belgium & MALVERN, Pa. & TOKYO — H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G sTREM2 assay for the fully automated ...

Fujirebio Receives Marketing Clearance for Lumipulse® G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-vitro Diagnostic Test as an Aid to Identify Patients With Amyloid Pathology Associated With Alzhe ...

—First Blood-Based In-Vitro Diagnostic Test to Receive FDA Clearance for Patients Being Assessed for Alzheimer’s Disease. — —Availability of Accurate, Accessible, Blood-Based Diagnostic ...

The Lumipulse G test, developed by Fujirebio Diagnostics, measures the ratio between two proteins in the bloodstream—pTau-217 and beta amyloid 1-42—and ties its findings to the likelihood of ...

Fujirebio today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Lumipulse ® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic ...

The US Food and Drug Administration (FDA) has approved Fujirebio Diagnostics’ Alzheimer’s disease (AD) blood test to help detect the neurodegenerative disease earlier. The decision makes the ...

The Lumipulse pTau 217/ β-Amyloid 1-42 Plasma Ratio test uses Fujirebio’s fully automated LUMIPULSE ® G1200 instrument system, which is widely available in clinical laboratories throughout the U.S.

Fujirebio announced that the US Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Lumipulse G pTau 217/ß-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) test for ...